Skip to main content
. 2016 Nov 4;6:36002. doi: 10.1038/srep36002

Figure 4. Administration of IL-25 attenuates CIA development in mice.

Figure 4

Male DBA/1 mice were immunized with CII to induce arthritis, and received rmIL-25 (1 μg/mice) or PBS for 5 consecutive days beginning on day 1 after the second immunization with CII. Mice were killed on day 36 for experimental analysis. Incidence (A) and mean clinical scores (B) of CIA in mice treated with rmIL-25 or PBS (n = 10 per group). (C) Representative H&E staining of knee joints of rmIL-25 or PBS treated mice with CIA. Scale bars, 500 μm. (D) Evaluation results for synovitis, pannus, and erosion of bone and cartilage in the knee joint sections of rmIL-25 or PBS treated mice with CIA. (E,F) Serum levels of CII-specific immunoglobulin G2a (IgG1) and IgG2a antibodies were measured by ELISA. Data are presented as the mean ± SEM of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.